Shopping Cart 0
Cart Subtotal
USD 0

EpiCast Report: Type 2 Diabetes-Epidemiology Forecast to 2026

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 3995

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 7990

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 11985

Details

EpiCast Report: Type 2 Diabetes-Epidemiology Forecast to 2026

Summary

Type 2 diabetes (T2D), formerly known as non-insulin dependent diabetes mellitus or adult-onset diabetes mellitus, is a chronic disorder of glucose equilibrium that results from the body's inability to make use of available insulin along with relative insulin deficiency. T2D constitutes approximately 90-95% of all diabetes cases around the world, while type 1 diabetes and gestational diabetes make up the remaining 5-10% of cases. Lifestyle factors such as obesity, physical inactivity, and dietary habits are modifiable risk factors, and can therefore be controlled or prevented. Non-modifiable risk factors such as race/ethnicity, family history, and advancing age can also put a person at high risk for developing the disease. T2D is also associated with several comorbidities including chronic kidney disease, cardiovascular disease, hypertension, and dyslipidemia.

In the 7MM, GlobalData epidemiologists forecast an increase in the diagnosed prevalent cases of T2D from 56,060,328 diagnosed prevalent cases in 2016 to 77,823,223 diagnosed prevalent cases in 2026, with an annual growth rate (AGR) of 3.88% during the forecast period. The US will have the highest number of diagnosed prevalent cases of T2D among the 7MM throughout the forecast period, while Italy will have the lowest.

GlobalData's epidemiological forecast for the diagnosed prevalence of T2D in the 7MM is supported by longitudinal historical data, which provide detailed insights into the epidemiology of the disease in each market, from studies conducted in these respective countries. GlobalData epidemiologists used nationally representative, country-specific studies published in peer-reviewed journals or national healthcare databases to forecast the prevalent cases of diagnosed T2D in all of the 7MM. GlobalData epidemiologists also segment the diagnosed prevalent cases of T2D in each country by age and sex, and into the major comorbidities of T2D.

Scope

The Type 2 Diabetes (T2D) EpiCast Report provides an overview of the risk factors, comorbidities, and global trends of T2D in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the diagnosed prevalent cases of T2D segmented by age (for ages 20 years and older) and sex in these markets. Additionally, the report provides a forecast of the major comorbidities of T2D, such as chronic kidney disease, cardiovascular disease, obesity, hypertension, and dyslipidemia in the diagnosed T2D prevalent pool.

The T2D epidemiology report is written and developed by Masters-and PhD-level epidemiologists.

The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

The T2D EpiCast report will allow you to-

Develop business strategies by understanding the trends shaping and driving the global T2D market.

Quantify patient populations in the global T2D market to improve product design, pricing, and launch plans.

Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for T2D therapeutics in each of the markets covered.

Identify the percentage of T2D diagnosed prevalent cases by age, sex, and major comorbid disorders.

READ MORE

Table Of Content

Scope

1 Table of Contents

1 Table of Contents 2

1.1 List of Tables 3

1.2 List of Figures 3

2 Executive Summary 4

2.1 Related Reports 5

2.2 Upcoming Reports 6

3 Epidemiology 7

3.1 Disease Background 7

3.2 Risk Factors and Comorbidities 7

3.3 Global and Historical Trends 8

3.4 Forecast Methodology 10

3.4.1 Sources 10

3.4.2 Forecast Assumptions and Methods 16

3.4.3 Diagnosed Prevalent Cases of T2D 16

3.5 Epidemiological Forecast for T2D (2016-2026) 23

3.5.1 Diagnosed Prevalent Cases of T2D 23

3.5.2 Age-Specific Diagnosed Prevalent Cases of T2D 24

3.5.3 Sex-Specific Diagnosed Prevalent Cases of T2D 25

3.5.4 Comorbidities Among the Diagnosed Prevalent Cases of T2D 26

3.6 Discussion 31

3.6.1 Epidemiological Forecast Insight 31

3.6.2 Limitations of Analysis 31

3.6.3 Strengths of Analysis 32

4 Appendix 34

4.1 Bibliography 34

4.2 About the Authors 38

4.2.1 Epidemiologist 38

4.2.2 Reviewers 38

4.2.3 Global Director of Therapy Analysis and Epidemiology 39

4.2.4 Global Head and EVP of Healthcare Operations and Strategy 39

4.3 About GlobalData 40

4.4 Contact Us 40

4.5 Disclaimer 40


List Of Figure

1.2 List of Figures

Figure 1: 7MM, Diagnosed Prevalent Cases of T2D, Both Sexes, Ages ?20 Years, 2016 and 2026 5

Figure 2: 7MM, Age-Standardized Diagnosed Prevalence (%) of T2D, Men, Ages ?20 Years, 2006-2026 9

Figure 3: 7MM, Age-Standardized Diagnosed Prevalence (%) of T2D, Women, Ages ?20 Years, 2006-2026 10

Figure 4: 7MM, Sources Used and Not Used, Diagnosed Prevalent Cases of T2D 11

Figure 5: 7MM, Sources Used, Prevalent Cases of CKD Among the Diagnosed Prevalent Cases of T2D 12

Figure 6: 7MM, Sources Used, Prevalent Cases of CVD Among the Diagnosed Prevalent Cases of T2D 13

Figure 7: 7MM, Sources Used, Prevalent Cases of Obesity Among the Diagnosed Prevalent Cases of T2D 14

Figure 8: 7MM, Sources Used, Prevalent Cases of Hypertension Among the Diagnosed Prevalent Cases of T2D 15

Figure 9: 7MM, Sources Used, Prevalent Cases of Dyslipidemia Among the Diagnosed Prevalent Cases of T2D 16

Figure 10: 7MM, Age-Specific Diagnosed Prevalent Cases of T2D, Ages ?20 Years, Both Sexes, N, 2016 25

Figure 11 : 7MM, Sex-Specific Diagnosed Prevalent Cases of T2D, Ages ?20 Years, N, 2016 26

Figure 12: 7MM, Prevalent Cases of CKD Among the Diagnosed Prevalent Cases of T2D, Ages ?20 Years, Both Sexes, N, 2016 27

Figure 13: 7MM, Prevalent Cases of CVD Among the Diagnosed Prevalent Cases of T2D, Ages ?20 Years, Both Sexes, N, 2016 28

Figure 14: 7MM, Prevalent Cases of Obesity Among the Diagnosed Prevalent Cases of T2D, Ages ?20 Years, Both Sexes, N, 2016 29

Figure 15: 7MM, Prevalent Cases of Hypertension Among the Diagnosed Prevalent Cases of T2D, Ages ?20 Years, Both Sexes, N, 2016 30

Figure 16: 7MM, Prevalent Cases of Dyslipidemia Among the Diagnosed Prevalent Cases of T2D, Ages ?20 Years, Both Sexes, N, 2016 31


List Of Table

1.1 List of Tables

Table 1: Risk Factors and Comorbidities for T2D. 8

Table 2: 7MM, Diagnosed Prevalent Cases of T2D, Ages ?20 Years, Both Sexes, N, Selected Years 2016-2026 24

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Company Profile

Company Profile Title

EpiCast Report: Type 2 Diabetes-Epidemiology Forecast to 2026

Summary

Type 2 diabetes (T2D), formerly known as non-insulin dependent diabetes mellitus or adult-onset diabetes mellitus, is a chronic disorder of glucose equilibrium that results from the body's inability to make use of available insulin along with relative insulin deficiency. T2D constitutes approximately 90-95% of all diabetes cases around the world, while type 1 diabetes and gestational diabetes make up the remaining 5-10% of cases. Lifestyle factors such as obesity, physical inactivity, and dietary habits are modifiable risk factors, and can therefore be controlled or prevented. Non-modifiable risk factors such as race/ethnicity, family history, and advancing age can also put a person at high risk for developing the disease. T2D is also associated with several comorbidities including chronic kidney disease, cardiovascular disease, hypertension, and dyslipidemia.

In the 7MM, GlobalData epidemiologists forecast an increase in the diagnosed prevalent cases of T2D from 56,060,328 diagnosed prevalent cases in 2016 to 77,823,223 diagnosed prevalent cases in 2026, with an annual growth rate (AGR) of 3.88% during the forecast period. The US will have the highest number of diagnosed prevalent cases of T2D among the 7MM throughout the forecast period, while Italy will have the lowest.

GlobalData's epidemiological forecast for the diagnosed prevalence of T2D in the 7MM is supported by longitudinal historical data, which provide detailed insights into the epidemiology of the disease in each market, from studies conducted in these respective countries. GlobalData epidemiologists used nationally representative, country-specific studies published in peer-reviewed journals or national healthcare databases to forecast the prevalent cases of diagnosed T2D in all of the 7MM. GlobalData epidemiologists also segment the diagnosed prevalent cases of T2D in each country by age and sex, and into the major comorbidities of T2D.

Scope

The Type 2 Diabetes (T2D) EpiCast Report provides an overview of the risk factors, comorbidities, and global trends of T2D in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the diagnosed prevalent cases of T2D segmented by age (for ages 20 years and older) and sex in these markets. Additionally, the report provides a forecast of the major comorbidities of T2D, such as chronic kidney disease, cardiovascular disease, obesity, hypertension, and dyslipidemia in the diagnosed T2D prevalent pool.

The T2D epidemiology report is written and developed by Masters-and PhD-level epidemiologists.

The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

The T2D EpiCast report will allow you to-

Develop business strategies by understanding the trends shaping and driving the global T2D market.

Quantify patient populations in the global T2D market to improve product design, pricing, and launch plans.

Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for T2D therapeutics in each of the markets covered.

Identify the percentage of T2D diagnosed prevalent cases by age, sex, and major comorbid disorders.

READ MORE

Scope

1 Table of Contents

1 Table of Contents 2

1.1 List of Tables 3

1.2 List of Figures 3

2 Executive Summary 4

2.1 Related Reports 5

2.2 Upcoming Reports 6

3 Epidemiology 7

3.1 Disease Background 7

3.2 Risk Factors and Comorbidities 7

3.3 Global and Historical Trends 8

3.4 Forecast Methodology 10

3.4.1 Sources 10

3.4.2 Forecast Assumptions and Methods 16

3.4.3 Diagnosed Prevalent Cases of T2D 16

3.5 Epidemiological Forecast for T2D (2016-2026) 23

3.5.1 Diagnosed Prevalent Cases of T2D 23

3.5.2 Age-Specific Diagnosed Prevalent Cases of T2D 24

3.5.3 Sex-Specific Diagnosed Prevalent Cases of T2D 25

3.5.4 Comorbidities Among the Diagnosed Prevalent Cases of T2D 26

3.6 Discussion 31

3.6.1 Epidemiological Forecast Insight 31

3.6.2 Limitations of Analysis 31

3.6.3 Strengths of Analysis 32

4 Appendix 34

4.1 Bibliography 34

4.2 About the Authors 38

4.2.1 Epidemiologist 38

4.2.2 Reviewers 38

4.2.3 Global Director of Therapy Analysis and Epidemiology 39

4.2.4 Global Head and EVP of Healthcare Operations and Strategy 39

4.3 About GlobalData 40

4.4 Contact Us 40

4.5 Disclaimer 40


List Of Figure

1.2 List of Figures

Figure 1: 7MM, Diagnosed Prevalent Cases of T2D, Both Sexes, Ages ?20 Years, 2016 and 2026 5

Figure 2: 7MM, Age-Standardized Diagnosed Prevalence (%) of T2D, Men, Ages ?20 Years, 2006-2026 9

Figure 3: 7MM, Age-Standardized Diagnosed Prevalence (%) of T2D, Women, Ages ?20 Years, 2006-2026 10

Figure 4: 7MM, Sources Used and Not Used, Diagnosed Prevalent Cases of T2D 11

Figure 5: 7MM, Sources Used, Prevalent Cases of CKD Among the Diagnosed Prevalent Cases of T2D 12

Figure 6: 7MM, Sources Used, Prevalent Cases of CVD Among the Diagnosed Prevalent Cases of T2D 13

Figure 7: 7MM, Sources Used, Prevalent Cases of Obesity Among the Diagnosed Prevalent Cases of T2D 14

Figure 8: 7MM, Sources Used, Prevalent Cases of Hypertension Among the Diagnosed Prevalent Cases of T2D 15

Figure 9: 7MM, Sources Used, Prevalent Cases of Dyslipidemia Among the Diagnosed Prevalent Cases of T2D 16

Figure 10: 7MM, Age-Specific Diagnosed Prevalent Cases of T2D, Ages ?20 Years, Both Sexes, N, 2016 25

Figure 11 : 7MM, Sex-Specific Diagnosed Prevalent Cases of T2D, Ages ?20 Years, N, 2016 26

Figure 12: 7MM, Prevalent Cases of CKD Among the Diagnosed Prevalent Cases of T2D, Ages ?20 Years, Both Sexes, N, 2016 27

Figure 13: 7MM, Prevalent Cases of CVD Among the Diagnosed Prevalent Cases of T2D, Ages ?20 Years, Both Sexes, N, 2016 28

Figure 14: 7MM, Prevalent Cases of Obesity Among the Diagnosed Prevalent Cases of T2D, Ages ?20 Years, Both Sexes, N, 2016 29

Figure 15: 7MM, Prevalent Cases of Hypertension Among the Diagnosed Prevalent Cases of T2D, Ages ?20 Years, Both Sexes, N, 2016 30

Figure 16: 7MM, Prevalent Cases of Dyslipidemia Among the Diagnosed Prevalent Cases of T2D, Ages ?20 Years, Both Sexes, N, 2016 31


List Of Table

1.1 List of Tables

Table 1: Risk Factors and Comorbidities for T2D. 8

Table 2: 7MM, Diagnosed Prevalent Cases of T2D, Ages ?20 Years, Both Sexes, N, Selected Years 2016-2026 24

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS